Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Blueprint Medicines Corp

Current price
102.36 USD -1.52 USD (-1.46%)
Last closed 102.81 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 451 419 136 USD
Yield for 12 month +81.46 %
21.11.2021 - 28.11.2021

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 45 Sidney Street, Cambridge, MA, United States, 02139

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

119.41 USD

P/E ratio

Dividend Yield

Current Year

+249 380 000 USD

Last Year

+204 036 000 USD

Current Quarter

+96 116 000 USD

Last Quarter

+71 957 000 USD

Current Year

+224 919 000 USD

Last Year

+186 223 000 USD

Current Quarter

+88 115 001 USD

Last Quarter

+70 166 000 USD

Key Figures BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -428 102 016 USD
Operating Margin TTM -82.01 %
PE Ratio
Return On Assets TTM -24.4 %
PEG Ratio
Return On Equity TTM -79.53 %
Wall Street Target Price 119.41 USD
Revenue TTM 282 208 992 USD
Book Value 4.96 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 51.9 %
Dividend Yield
Gross Profit TTM 177 275 000 USD
Earnings per share -4.82 USD
Diluted Eps TTM -4.82 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -102.15 %

Dividend Analytics BPMC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 19.9069
Price Sales TTM 21.4232
Enterprise Value EBITDA -10.5545
Price Book MRQ 40.9047

Financials BPMC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BPMC

For 52 weeks

43.89 USD 111.02 USD
50 Day MA 95.77 USD
Shares Short Prior Month 4 540 988
200 Day MA 75.09 USD
Short Ratio 6.26
Shares Short 4 522 493
Short Percent 8.15 %

Dynamics of changes in the value of assets




430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds



14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics